NDAC
This article was originally published in The Tan Sheet
Executive Summary
Meeting slated for Oct. 18-19 has been canceled. No agenda has been set for the next scheduled meeting dates of Dec. 2-3. Most recently, NDAC met jointly with the Arthritis Advisory Committee July 20 to consider the Rx-to-OTC switch of Merck's Flexeril 5 mg (1"The Tan Sheet" July 26, pp. 3-9)
You may also be interested in...
Flexeril Indications Self-Diagnosis Seen As Significant Hurdle By Committee
The ability of patients to accurately detect when they would need to use Flexeril 5 mg (cyclobenzaprine) is a significant hurdle the drug would need to overcome in a switch from the Rx to the OTC environment, according to discussions by FDA's Nonprescription Drugs and Arthritis Advisory Committees July 20.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands